BriaCell Therapeutics Corp. (BCTX)
NASDAQ: BCTX · Real-Time Price · USD
0.740
+0.138 (22.88%)
Nov 21, 2024, 1:19 PM EST - Market open
BriaCell Therapeutics Income Statement
Financials in millions USD. Fiscal year is August - July.
Millions USD. Fiscal year is Aug - Jul.
TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
Jul '24 Jul 31, 2024 | Jul '24 Jul 31, 2024 | Jul '23 Jul 31, 2023 | Jul '22 Jul 31, 2022 | Jul '21 Jul 31, 2021 | Jul '20 Jul 31, 2020 |
Selling, General & Admin | 6.65 | 6.65 | 8.51 | 7.58 | 4.96 | 1.54 | |
Research & Development | 26.68 | 26.68 | 14.76 | 7.71 | 2.02 | 2.4 | |
Operating Expenses | 33.33 | 33.33 | 23.27 | 15.29 | 6.98 | 3.94 | |
Operating Income | -33.33 | -33.33 | -23.27 | -15.29 | -6.98 | -3.94 | |
Interest Expense | - | - | - | -0 | -0.08 | -0.03 | |
Interest & Investment Income | 0.29 | 0.29 | 0.89 | 0.14 | 0 | - | |
Earnings From Equity Investments | -0.11 | -0.11 | - | - | - | - | |
Currency Exchange Gain (Loss) | -0.03 | -0.03 | -0.04 | -0.03 | -2.18 | -0.01 | |
Other Non Operating Income (Expenses) | 28.24 | 28.24 | 2.12 | -11.65 | -4.45 | 0.02 | |
EBT Excluding Unusual Items | -4.93 | -4.93 | -20.3 | -26.84 | -13.67 | -3.96 | |
Other Unusual Items | - | - | - | - | -0.14 | -0.06 | |
Pretax Income | -4.93 | -4.93 | -20.3 | -26.84 | -13.82 | -4.02 | |
Earnings From Continuing Operations | -4.93 | -4.93 | -20.3 | -26.84 | -13.82 | -4.02 | |
Minority Interest in Earnings | 0.14 | 0.14 | - | - | - | - | |
Net Income | -4.79 | -4.79 | -20.3 | -26.84 | -13.82 | -4.02 | |
Net Income to Common | -4.79 | -4.79 | -20.3 | -26.84 | -13.82 | -4.02 | |
Shares Outstanding (Basic) | 16 | 16 | 16 | 15 | 5 | 1 | |
Shares Outstanding (Diluted) | 16 | 16 | 16 | 15 | 5 | 1 | |
Shares Change (YoY) | 5.35% | 5.35% | 0.81% | 242.82% | 533.09% | 23.16% | |
EPS (Basic) | -0.29 | -0.29 | -1.30 | -1.73 | -3.06 | -5.64 | |
EPS (Diluted) | -0.29 | -0.29 | -1.30 | -1.73 | -3.06 | -5.64 | |
Free Cash Flow | -24.58 | -24.58 | -23.74 | -12.48 | -7.75 | -1.27 | |
Free Cash Flow Per Share | -1.49 | -1.49 | -1.52 | -0.81 | -1.71 | -1.77 | |
EBITDA | -33.25 | -33.25 | -23.26 | -15.27 | -6.96 | -3.92 | |
D&A For EBITDA | 0.08 | 0.08 | 0.02 | 0.02 | 0.02 | 0.02 | |
EBIT | -33.33 | -33.33 | -23.27 | -15.29 | -6.98 | -3.94 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.